Global investment bank Morgan Stanley has maintained an overweight rating on Kaynes Technology but raised the target price to Rs 3,845 from Rs 2,440, while Macquarie maintained a sell rating on Zomato with a target price of Rs 100.

Sebi proposes to revise criteria for derivatives market, potentially adding 78 stocks like LIC, Zomato, YES Bank. Changes include higher thresholds for order size, market-wide position limits, and introducing Product Success Framework for single-stock derivatives after 6 months.

Global investment firm BlackRock likely sold a 15% stake in Mphasis, leading to a 3.7% share price drop. It's the year's second-largest block deal. Blackstone, owning 55.45%, will drop to 40.4% after the deal. Mphasis specializes in IT services, especially in BFSI. Last year, shares rose 27.5%, but in 2024, they fell 13.6%.

Domestic markets navigated a volatile week, ending near all-time highs. Bajaj Finance filed for a Rs 7,000 crore IPO, Kronox Lab to debut with 30% premium, Godawari Power eyes share buyback, Dr Reddy's unit gets FDA observations, and Jubilant Pharmova faces FDA scrutiny.

On Friday, equity indices surged by over 2%, reaching record highs following the Reserve Bank of India (RBI) upward revision of the GDP growth projection. Notable stocks included HDFC AMC, which increased by 2%, Wipro, witnessing a 5% gain, and Paytm, whose shares soared by 10% on Friday.

Nifty extended its pullback and went on to end the day on a robust note.

Bajaj Auto, part of the auto space, doubled investors’ wealth in the last year, hitting a record high in June 2024. Analysts suggest further upside potential with technical indicators supporting the bullish trend.

Global investment bank Morgan Stanley has maintained an overweight rating on Kaynes Technology but raised the target price to Rs 3,845 from Rs 2,440, while Macquarie maintained a sell rating on Zomato with a target price of Rs 100.

Nifty extended its pullback and went on to end the day on a robust note.

Indian benchmark equity indices, Sensex and Nifty50, reached fresh record highs on Monday with Sensex hitting the 77,000 mark.

Tata Consumer Products, in FMCG space, saw profit-taking but stock up 40% in a year. Rally not over. Stock reached 52-week high of 1269 in March 2024. Analyst recommends accumulating stock in range 1120-1140 for target of 1325-1330 levels with stop loss below 1050. Disclaimer: Recommendations, suggestions, views, and opinions given by experts are their own.

A favourable wealth effect, driven by a sharp rise in the equity markets, is enticing many first-time homebuy ers to take the plunge, while affluent buyers are looking for second homes. If you are a fence-sitter, still unsure about when to buy a house, this market presents a big dilemma. Is it the right time to buy a house?

The longer the tenure of a loan, the higher the interest burden. Home loan rates will not come down as the RBI has kept policy rates unchanged. If you are planning to buy a house with a loan, ET Wealth suggests some ways to reduce the cost of borrowing.

Domestic markets navigated a volatile week, ending near all-time highs. Bajaj Finance filed for a Rs 7,000 crore IPO, Kronox Lab to debut with 30% premium, Godawari Power eyes share buyback, Dr Reddy's unit gets FDA observations, and Jubilant Pharmova faces FDA scrutiny.

On Friday, equity indices surged by over 2%, reaching record highs following the Reserve Bank of India (RBI) upward revision of the GDP growth projection. Notable stocks included HDFC AMC, which increased by 2%, Wipro, witnessing a 5% gain, and Paytm, whose shares soared by 10% on Friday.

Tata Consumer Products, in FMCG space, saw profit-taking but stock up 40% in a year. Rally not over. Stock reached 52-week high of 1269 in March 2024. Analyst recommends accumulating stock in range 1120-1140 for target of 1325-1330 levels with stop loss below 1050. Disclaimer: Recommendations, suggestions, views, and opinions given by experts are their own.

Domestic markets navigated a volatile week, ending near all-time highs. Bajaj Finance filed for a Rs 7,000 crore IPO, Kronox Lab to debut with 30% premium, Godawari Power eyes share buyback, Dr Reddy's unit gets FDA observations, and Jubilant Pharmova faces FDA scrutiny.

On Friday, equity indices surged by over 2%, reaching record highs following the Reserve Bank of India (RBI) upward revision of the GDP growth projection. Notable stocks included HDFC AMC, which increased by 2%, Wipro, witnessing a 5% gain, and Paytm, whose shares soared by 10% on Friday.

Japan's Nikkei share average edged up on Monday as export-related stocks rose on a weaker yen following stronger-than-expected U.S. jobs data and a rise in domestic yields boosted financial stocks.

Tata Consumer Products, in FMCG space, saw profit-taking but stock up 40% in a year. Rally not over. Stock reached 52-week high of 1269 in March 2024. Analyst recommends accumulating stock in range 1120-1140 for target of 1325-1330 levels with stop loss below 1050. Disclaimer: Recommendations, suggestions, views, and opinions given by experts are their own.

Domestic markets navigated a volatile week, ending near all-time highs. Bajaj Finance filed for a Rs 7,000 crore IPO, Kronox Lab to debut with 30% premium, Godawari Power eyes share buyback, Dr Reddy's unit gets FDA observations, and Jubilant Pharmova faces FDA scrutiny.

On Friday, equity indices surged by over 2%, reaching record highs following the Reserve Bank of India (RBI) upward revision of the GDP growth projection. Notable stocks included HDFC AMC, which increased by 2%, Wipro, witnessing a 5% gain, and Paytm, whose shares soared by 10% on Friday.

Tata Consumer Products, in FMCG space, saw profit-taking but stock up 40% in a year. Rally not over. Stock reached 52-week high of 1269 in March 2024. Analyst recommends accumulating stock in range 1120-1140 for target of 1325-1330 levels with stop loss below 1050. Disclaimer: Recommendations, suggestions, views, and opinions given by experts are their own.

Domestic markets navigated a volatile week, ending near all-time highs. Bajaj Finance filed for a Rs 7,000 crore IPO, Kronox Lab to debut with 30% premium, Godawari Power eyes share buyback, Dr Reddy's unit gets FDA observations, and Jubilant Pharmova faces FDA scrutiny.

Investors await next week's inflation data and Fed meeting for signals on stock market trajectory amid conflicting economic signals. S&P 500's 12% YTD rise hinges on Fed's ability to manage inflation without hampering growth.

Tata Consumer Products, in FMCG space, saw profit-taking but stock up 40% in a year. Rally not over. Stock reached 52-week high of 1269 in March 2024. Analyst recommends accumulating stock in range 1120-1140 for target of 1325-1330 levels with stop loss below 1050. Disclaimer: Recommendations, suggestions, views, and opinions given by experts are their own.

Domestic markets navigated a volatile week, ending near all-time highs. Bajaj Finance filed for a Rs 7,000 crore IPO, Kronox Lab to debut with 30% premium, Godawari Power eyes share buyback, Dr Reddy's unit gets FDA observations, and Jubilant Pharmova faces FDA scrutiny.

Asian stocks fell as traders reduced bets for Fed rate cuts due to a tight US labor market. A snap election in France raised political concerns, impacting the euro. MSCI's Asia-Pacific shares index also dropped.

Nifty's bullish setup is supported by strong technical indicators, with recommendations for specific stocks in FMCG, pharma, IT, auto, and power sectors for potential gains.

On Friday, the Indian market continued its upward trend, marking the third consecutive day of gains. The S&P BSE Sensex surged by over 1,600 points, while the Nifty50 closed just below the 23,300 level.

Tata Consumer Products, in FMCG space, saw profit-taking but stock up 40% in a year. Rally not over. Stock reached 52-week high of 1269 in March 2024. Analyst recommends accumulating stock in range 1120-1140 for target of 1325-1330 levels with stop loss below 1050. Disclaimer: Recommendations, suggestions, views, and opinions given by experts are their own.

Domestic markets navigated a volatile week, ending near all-time highs. Bajaj Finance filed for a Rs 7,000 crore IPO, Kronox Lab to debut with 30% premium, Godawari Power eyes share buyback, Dr Reddy's unit gets FDA observations, and Jubilant Pharmova faces FDA scrutiny.

Domestic equities ended the week near all-time highs despite election-related volatility. Analysts expect the upward bias to continue with focus on key economic data. State of the markets signals a negative start with Nifty futures trading lower at 23,267. India VIX rose to 16.88 levels. Brent crude futures slipped to $79.58 a barrel.

Foreign portfolio investors have been selling Indian shares ahead of the elections, focusing on growth stocks over defensive ones. Data from NSDL shows a decline in FMCG and IT sector weightage in FPIs' equity folio.

Anticipation surrounds the US Fed meeting this week, hinting at upcoming interest rate cuts based on fluctuating inflation progress in the first quarter.

Investors await next week's inflation data and Fed meeting for signals on stock market trajectory amid conflicting economic signals. S&P 500's 12% YTD rise hinges on Fed's ability to manage inflation without hampering growth.

​ Foreign investors withdrew nearly Rs 14,800 crore from domestic stocks in the first week of this month, influenced by India's Lok Sabha election results and attractive valuations of Chinese stocks.

On Friday, the Indian market continued its upward trend, marking the third consecutive day of gains. The S&P BSE Sensex surged by over 1,600 points, while the Nifty50 closed just below the 23,300 level.

Tata Consumer Products, in FMCG space, saw profit-taking but stock up 40% in a year. Rally not over. Stock reached 52-week high of 1269 in March 2024. Analyst recommends accumulating stock in range 1120-1140 for target of 1325-1330 levels with stop loss below 1050. Disclaimer: Recommendations, suggestions, views, and opinions given by experts are their own.

Domestic markets navigated a volatile week, ending near all-time highs. Bajaj Finance filed for a Rs 7,000 crore IPO, Kronox Lab to debut with 30% premium, Godawari Power eyes share buyback, Dr Reddy's unit gets FDA observations, and Jubilant Pharmova faces FDA scrutiny.

Le Travenues Technology, the promoter of Ixigo, is raising ₹740 crore through an IPO, with a fresh issue of ₹120 crore and an OFS of ₹620 crore.

Tata Consumer Products, in FMCG space, saw profit-taking but stock up 40% in a year. Rally not over. Stock reached 52-week high of 1269 in March 2024. Analyst recommends accumulating stock in range 1120-1140 for target of 1325-1330 levels with stop loss below 1050. Disclaimer: Recommendations, suggestions, views, and opinions given by experts are their own.

Domestic markets navigated a volatile week, ending near all-time highs. Bajaj Finance filed for a Rs 7,000 crore IPO, Kronox Lab to debut with 30% premium, Godawari Power eyes share buyback, Dr Reddy's unit gets FDA observations, and Jubilant Pharmova faces FDA scrutiny.

“A fresh breakout occurred as the Tata Consumer stock managed to surpass its falling trend line of the downward sloping channel. Traders can buy for a target of Rs 1330 in the next 5-6 weeks,” Shitij Gandhi, Senior Technical Analyst, SMC Global Securities, said.

Saudi Aramco's latest offering raised $11.2 billion with international investors acquiring the majority of shares. The Gulf kingdom aims to boost finances for large-scale projects in preparation for a post-oil future.

Tech stocks face diverging performances as Nvidia leads the pack, while Apple struggles, causing a profit cool down and an emerging asymmetry among Big Tech stocks, affecting the overall earnings potential in 2024.

​ Foreign investors withdrew nearly Rs 14,800 crore from domestic stocks in the first week of this month, influenced by India's Lok Sabha election results and attractive valuations of Chinese stocks.

On Friday, the Indian market continued its upward trend, marking the third consecutive day of gains. The S&P BSE Sensex surged by over 1,600 points, while the Nifty50 closed just below the 23,300 level.

Tata Consumer Products, in FMCG space, saw profit-taking but stock up 40% in a year. Rally not over. Stock reached 52-week high of 1269 in March 2024. Analyst recommends accumulating stock in range 1120-1140 for target of 1325-1330 levels with stop loss below 1050. Disclaimer: Recommendations, suggestions, views, and opinions given by experts are their own.

Domestic markets navigated a volatile week, ending near all-time highs. Bajaj Finance filed for a Rs 7,000 crore IPO, Kronox Lab to debut with 30% premium, Godawari Power eyes share buyback, Dr Reddy's unit gets FDA observations, and Jubilant Pharmova faces FDA scrutiny.